Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient

BACKGROUND: In the field of breast cancer tumor biology, triple-negative breast cancer patients are the main focus of current clinical trials exploring the use of immune checkpoint inhibitors due to higher frequencies of somatic mutations, neoantigens, and resulting tumor-specific T-cell reactivity....

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Breast Care (Basel)
Main Authors: Fremd, Carlo, Hlevnjak, Mario, Zapatka, Marc, Zoernig, Inka, Halama, Niels, Fejzibegovic, Nino, Thewes, Verena, Lichter, Peter, Schirmacher, Peter, Kloor, Matthias, Marmé, Frederik, Schütz, Florian, Kosaloglu, Zeynep, Sinn, Hans Peter, Jäger, Dirk, Schneeweiss, Andreas
Formato: Artigo
Idioma:Inglês
Publicado em: S. Karger GmbH 2019
Assuntos:
Novel Insights from Clinical Practice
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6465703/
https://ncbi.nlm.nih.gov/pubmed/31019444
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1159/000492580
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados